Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

3.04EUR
29 Jul 2016
Change (% chg)

€-0.03 (-1.04%)
Prev Close
€3.07
Open
€3.02
Day's High
€3.10
Day's Low
€3.02
Volume
5,586
Avg. Vol
15,472
52-wk High
€5.37
52-wk Low
€2.71

THR.BR

Chart for THR.BR

About

ThromboGenics NV is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. The Company’s lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was... (more)

Overall

Beta: 0.85
Market Cap(Mil.): €109.65
Shares Outstanding(Mil.): 36.09
Dividend: --
Yield (%): --

Financials

  THR.BR Industry Sector
P/E (TTM): -- 42.29 39.28
EPS (TTM): -1.05 -- --
ROI: -20.07 -8.76 14.40
ROE: -20.05 -8.92 15.47

BRIEF-Thrombogenics receives FDA approval for JETREA

* Receives US FDA approval for new 'already-diluted' formulation of JETREA

Jun 08 2016

BRIEF-Thrombogenics cash position at end March down at 96.9 mln euros

* Cash and investments were 96.9 million euros as of end of March 2016, vs 101.4 million euros a at end of Dec. 2015 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 13 2016

BRIEF-Thrombogenics says Oncurious and Bioinvent partner with U.S. research consortium

* Says Oncurious NV and Bioinvent partner with U.S. research consortium to accelerate phase I/IIa clinical development of TB-403 Source text: http://bit.ly/251lYUL Further company coverage: (Gdynia Newsroom:)

Mar 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Sadif Analytics Prime
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.